Liquidia Technologies (LQDA)
(Delayed Data from NSDQ)
$12.53 USD
+0.16 (1.29%)
Updated Apr 26, 2024 04:00 PM ET
After-Market: $12.51 -0.02 (-0.16%) 7:58 PM ET
3-Hold of 5 3
F Value D Growth B Momentum F VGM
Brokerage Reports
0 items in cart
Liquidia Technologies, Inc. [LQDA]
Reports for Purchase
Showing records 81 - 100 ( 128 total )
Company: Liquidia Technologies, Inc.
Industry: Medical - Biomedical and Genetics
CRL In-Line with Expectations; Limited Catalysts over the Next 12-months
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: Liquidia Technologies, Inc.
Industry: Medical - Biomedical and Genetics
Company: Liquidia Technologies, Inc.
Industry: Medical - Biomedical and Genetics
D/g to NEUTRAL; Likely Negative PDUFA Decision - Lack of Catalysts in 2021
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: Liquidia Technologies, Inc.
Industry: Medical - Biomedical and Genetics
Company: Liquidia Technologies, Inc.
Industry: Medical - Biomedical and Genetics
Company: Liquidia Technologies, Inc.
Industry: Medical - Biomedical and Genetics
Mixed IPR Outcome Likely Delays LIQ861 Launch Until 2022
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: Liquidia Technologies, Inc.
Industry: Medical - Biomedical and Genetics
Q2: Cash Runway into Q1:22; Next, LIQ861/PAH Nov 24, 2020 PDUFA Date
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: Liquidia Technologies, Inc.
Industry: Medical - Biomedical and Genetics
Company: Liquidia Technologies, Inc.
Industry: Medical - Biomedical and Genetics
Company: Liquidia Technologies, Inc.
Industry: Medical - Biomedical and Genetics
Liquidia Acquires RareGen in All-Stock Deal - Expands PAH Market Opportunity
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: Liquidia Technologies, Inc.
Industry: Medical - Biomedical and Genetics
Company: Liquidia Technologies, Inc.
Industry: Medical - Biomedical and Genetics
Company: Liquidia Technologies, Inc.
Industry: Medical - Biomedical and Genetics
TYVASO® Patent Lawsuit Could Be Resolved in LQDAs Favor Before TreT Launch
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: Liquidia Technologies, Inc.
Industry: Medical - Biomedical and Genetics
Company: Liquidia Technologies, Inc.
Industry: Medical - Biomedical and Genetics
Company: Liquidia Technologies, Inc.
Industry: Medical - Biomedical and Genetics
Final LIQ861 Ph3 INSPIRE Trial Results Presented at ISHLTv
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: Liquidia Technologies, Inc.
Industry: Medical - Biomedical and Genetics
LIQ861/PAH: FDA Accepted NDA for Review - Set PDUFA to November 24, 2020
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: Liquidia Technologies, Inc.
Industry: Medical - Biomedical and Genetics
Q4/FY19 Financials; We Anticipate LIQ861/PAH NDA Acceptance for Review in Q1
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: Liquidia Technologies, Inc.
Industry: Medical - Biomedical and Genetics
HEALTHCARE - The Week Ahead in Life Sciences
Provider: WEDBUSH SECURITIES INC.
Analyst: Research Department
Company: Liquidia Technologies, Inc.
Industry: Medical - Biomedical and Genetics
HEALTHCARE - The Week Ahead in Life Sciences
Provider: WEDBUSH SECURITIES INC.
Analyst: Research Department